SPC453
Ritlecitinib eða lyfjafræðilega viðunandi salt þar af
Status:
VeittApplication date:
12.2.2024Application published:
15.3.2024Grant published:
15.11.2025
Max expiry date:
17.9.2038Medicine name:
LitfuloMedicine for children:
No
Timeline
Today
12.2.2024Application
15.3.2024Publication
15.11.2025Registration
17.9.2038Expires
Marketing license
IS authorization number:
EU/1/23/1755Date:
13.10.2023
Foreign authorization number:
EU/1/23/1755Date:
18.9.2023
Owner
Name:
Pfizer Inc.Address:
66 Hudson Boulevard East, New York, NY 10001-2192 US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113 Reykjavík
Patent
Number:
EP3077395
Deadlines
TypeDeadline until
Type: Formgallafrestur, fyrsti
Deadline until: 02.07.2024
Type: Frestur til að fara yfir drög að vottorði
Deadline until: 08.10.2025